{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.","groups":[{"description":"200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.","id":"OG000","title":"Multi-kinase Inhibitor Fosamatinib Disodium"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"23 months","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}